Daxor allocates $550K of May 2023 offering proceeds to hematocrit capability development

DAXOR CORP

Net proceeds of $3.56M from May 22, 2023 public offering of 410,260 shares at $9.75/share.
$550,000 reserved for proprietary hematocrit capability for next-generation technologies.
Development expected over 12 months, supported by Department of Defense efforts.
Funds are part of the previously stated use of proceeds for next-gen technology development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.